查看文章

Improving clinical outcomes for chronic diseases has given rise to the field of ultralong-acting medicines. These serve to improve regimen adherence by extending the apparent half-lives of drugs and as such affecting clinical outcomes for diseases. The diseases include chronic viral infection (s), tuberculosis, malaria, and opioid use disorder (OUD). Nonetheless, limitations abound in translating discoveries made in research laboratories to the clinic. With this in mind, we are aware of a recent roadblock in ultralong-acting (ULA) formulation development affecting the OUD clinical-translational research field that we wish to share with the readership of Neuroimmune Pharmacology and Therapeutics. This roadblock is focused on drug implants. Titan Pharmaceuticals, Inc., working with Braeburn Pharmaceuticals, Inc., received US Food and Drug Administration (FDA) approval for the use of Probuphine, an ULA …